Skip to main content

Table 4 Microbiology of the patient cohort

From: Clinical course and significance of nontuberculous mycobacteria and its subtypes in cystic fibrosis

  Patients with Slow-growing NTM (N = 17) Patients with Rapidly Growing NTM (N = 8)  
N N (%) N N (%) P-value
Common bacterial colonization at time of positive NTMa 17   8   
P. aeruginosa   13 (76)   8 (100) 0.27
 Methicillin-susceptible S. aureus   13 (76)   5 (63) 0.64
 Methicillin-resistant S. aureus   6 (35)   3 (38) 0.99
S. maltophilia   4 (22)   4 (50) 0.36
Escherichia coli   1 (6)   0.99
A. baumannii    1 (13) 0.32
 None   1 (6)   0.99
History of ABPAb      
 Before NTM infection 17   8   0.53
  No   14 (82)   8 (100)
  Yes   3 (18)  
 After NTM infection 17   8   0.64
  No   13 (76)   5 (62)
  Yes   4 (24)   3 (38)
American Thoracic Society treatment criteria 16   6   
 Clinical   11 (69)   6 (100) 0.27
 New changes on chest x-ray or computed tomography   7 (44)   3 (50) 0.99
 Two positive sputum or bronchoalveolar lavage   11 (69)   4 (67) 0.99
Received treatment for NTM 16   8   0.58
 No   14 (88)   6 (75)
 Yes   2 (12)   2 (25)
  1. aNontuberculous mycobacteria
  2. bAllergic bronchopulmonary aspergillosis
\